Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 30, 2019대한비뇨기종양학회지Open Access

A Study on the Efficacy and Safety of Rivaroxaban in Urologic Cancer-Associated Venous Thromboembolism

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Although DOACs are recommended for cancer-associated venous thromboembolism, firm evidence regarding their efficacy and safety in patients with urologic cancer was lacking.

Does rivaroxaban reduce the composite event of clinically relevant bleeding or VTE recurrence in patients with urologic cancer-associated VTE compared to dalteparin?

Population

124 eligible VTE patients with urologic cancers

Comparison

Rivaroxaban vs dalteparin

Design

Retrospective medical record review

Authors

JLJang Ho LeeJLJang Ho LeeDYDalsan You

Discussion

Loading...

Member takes

Overview

Rivaroxaban may be considered for urologic cancer VTE; leaves open need for randomized confirmation in this population.

Structured PICO

Does rivaroxaban reduce the composite event of clinically relevant bleeding or VTE recurrence in patients with urologic cancer-associated VTE compared to dalteparin?

P
Population
124 patients with urologic cancer-associated venous thromboembolism (VTE)
I
Intervention
Rivaroxaban
C
Comparator
Dalteparin
O
Outcome
Composite event of clinically relevant bleeding or VTE recurrencecomposite

Rivaroxaban showed comparable efficacy and safety to dalteparin for treating cancer-associated VTE in patients with urologic cancer, supporting its use as a viable alternative.

Cite This Study

Lee et al. (2019) studied this question.

synapsesocial.com/papers/6a70f29cf44fa9f079deb3adhttps://doi.org/10.22465/kjuo.2019.17.3.178
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Rivaroxaban versus dalteparin for the treatment of cancer-associated venous thromboembolism: a systematic review and meta-analysis2025
  2. 2A Retrospective Study on Efficacy and Safety of Rivaroxaban and Dalteparin for Long-Term Treatment of Venous Thromboembolism in Patients with Lung Cancer2019 · 24 citations
  3. 3Effectiveness and Safety of Rivaroxaban and Low Molecular Weight Heparin in Cancer-Associated Venous Thromboembolism2023 · 21 citations
  4. 4Efficacy and safety of direct oral anticoagulants for preventing venous thromboembolism in hospitalized cancer patients: a national multicenter retrospective cohort study2024 · 7 citations
  5. 5Comparative analysis of enoxaparin versus rivaroxaban in the treatment of cancer associated venous thromboembolism: experience from a tertiary care cancer centre2020 · 13 citations